latanoprost · LATANOPROST .05 mg/mL · Solution/ Drops · Ophthalmic; Topical · Sun Pharmaceutical Industries, Inc.
NDC 47335-0317-92 · 3 BOTTLE, DROPPER in 1 BOX / 2.5 mL in 1 BOTTLE, DROPPER · NDA · View full market →
12 companies supply this market — deep enough that no single failure threatens the supply. One of its named manufacturing plants, Sun Pharmaceutical Industries Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 47335-0317-90) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 4 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
| Type | Number / code | Expires |
|---|---|---|
| patent | 9629852 | Sep 12, 2029 |
| patent | 9539262 | Oct 15, 2028 |
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Bausch & Lomb Incorporated | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Gland Pharma Limited | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Micro Labs Limited | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals,Inc. | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Proficient Rx LP | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Somerset Therapeutics, LLC | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | LATANOPROST .05 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Viatris Specialty LLC | LATANOPROST 50 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Xelpros — NDC 47335-0317-92," retrieved September 3, 2026, https://drugdashboards.com/drug/47335031792.
Free to cite with attribution — see how the data is put together.